Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Institute of Pediatrics and Department of Hematology and Oncology, Children's Hospital of Fudan University, National Children's Medical Center, and the Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
J Natl Cancer Inst. 2022 Sep 9;114(9):1287-1295. doi: 10.1093/jnci/djac101.
There is growing evidence for the inherited basis of susceptibility to childhood acute lymphoblastic leukemia (ALL). Genome-wide association studies have identified non-coding ALL risk variants at the ARID5B gene locus, but their exact functional effects and the molecular mechanism linking ARID5B to B-cell ALL leukemogenesis remain largely unknown.
We performed targeted sequencing of ARID5B in germline DNA of 5008 children with ALL. Variants were evaluated for association with ALL susceptibility using 3644 patients from the UK10K cohort as non-ALL controls, under an additive model. Cis-regulatory elements in ARID5B were systematically identified using dCas9-KRAB-mediated enhancer interference system enhancer screen in ALL cells. Disruption of transcription factor binding by ARID5B variant was predicted informatically and then confirmed using chromatin immunoprecipitation and coimmunoprecipitation. ARID5B variant association with hematological traits was examined using UK Biobank dataset. All statistical tests were 2-sided.
We identified 54 common variants in ARID5B statistically significantly associated with leukemia risk, all of which were noncoding. Six cis-regulatory elements at the ARID5B locus were discovered using CRISPR-based high-throughput enhancer screening. Strikingly, the top ALL risk variant (rs7090445, P = 5.57 × 10-45) is located precisely within the strongest enhancer element, which is also distally tethered to the ARID5B promoter. The variant allele disrupts the MEF2C binding motif sequence, resulting in reduced MEF2C affinity and decreased local chromosome accessibility. MEF2C influences ARID5B expression in ALL, likely via a transcription factor complex with RUNX1. Using the UK Biobank dataset (n = 349 861), we showed that rs7090445 was also associated with lymphocyte percentage and count in the general population (P = 8.6 × 10-22 and 2.1 × 10-18, respectively).
Our results indicate that ALL risk variants in ARID5B function by modulating cis-regulatory elements at this locus.
越来越多的证据表明,儿童急性淋巴细胞白血病(ALL)易感性具有遗传基础。全基因组关联研究已经在 ARID5B 基因座上确定了非编码 ALL 风险变异,但这些变异的确切功能影响以及将 ARID5B 与 B 细胞 ALL 白血病发生联系起来的分子机制在很大程度上仍然未知。
我们对 5008 名 ALL 患儿的胚系 DNA 进行了 ARID5B 的靶向测序。采用英国 10K 队列中的 3644 名非 ALL 对照患者,在加性模型下,评估变异与 ALL 易感性的关联。在 ALL 细胞中,使用 dCas9-KRAB 介导的增强子干扰系统增强子筛选,系统地鉴定了 ARID5B 中的顺式调控元件。通过染色质免疫沉淀和共免疫沉淀,从信息学上预测和验证了转录因子结合对 ARID5B 变异的破坏。使用英国生物库数据集检查 ARID5B 变异与血液学特征的关联。所有统计检验均为双侧检验。
我们发现 ARID5B 中存在 54 个与白血病风险统计学显著相关的常见变异,这些变异均为非编码变异。使用基于 CRISPR 的高通量增强子筛选,发现了 ARID5B 基因座上的 6 个顺式调控元件。令人惊讶的是,顶级 ALL 风险变异(rs7090445,P=5.57×10-45)恰好位于最强的增强子元件内,该元件也与 ARID5B 启动子远端相连。变异等位基因破坏了 MEF2C 结合基序序列,导致 MEF2C 亲和力降低和局部染色体可及性降低。MEF2C 可能通过与 RUNX1 形成转录因子复合物影响 ALL 中 ARID5B 的表达。使用英国生物库数据集(n=349861),我们表明 rs7090445 也与普通人群中的淋巴细胞百分比和计数相关(P=8.6×10-22 和 2.1×10-18)。
我们的研究结果表明,ARID5B 中的 ALL 风险变异通过调节该基因座的顺式调控元件发挥作用。